Compounds > kt 6149
Page last updated: 2024-09-02

kt 6149 and Ovarian Neoplasms

kt 6149 has been researched along with Ovarian Neoplasms in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's2 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
De Bruijn, EA; Dirix, LY; Gheuens, EE; van der Heyden, S; van Oosterom, AT1
Ardiet, C; Catimel, G; De Bruijn, E; Dirix, L; Tranchand, B; Van Oosterom, A; Verdonk, R1

Trials

1 trial(s) available for kt 6149 and Ovarian Neoplasms

ArticleYear
Phase I and pharmacokinetic study of KW-2149 given by 24 hours continuous infusion.
    Investigational new drugs, 1995, Volume: 13, Issue:2

    Topics: Antineoplastic Agents; Carcinoma; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drugs, Investigational; Female; Humans; Infusions, Intravenous; Lung; Male; Middle Aged; Mitomycin; Mitomycins; Ovarian Neoplasms

1995

Other Studies

1 other study(ies) available for kt 6149 and Ovarian Neoplasms

ArticleYear
Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
    Anti-cancer drugs, 1994, Volume: 5, Issue:3

    Topics: Animals; Colonic Neoplasms; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Kinetics; Mitomycin; Mitomycins; Ovarian Neoplasms; Rats; Tumor Cells, Cultured

1994